Cardio Diagnostics (NASDAQ:CDIO) Releases Earnings Results

Cardio Diagnostics (NASDAQ:CDIO) issued its earnings results on Friday. The company reported ($0.59) earnings per share (EPS) for the quarter, Zacks reports. Cardio Diagnostics had a negative return on equity of 82.28% and a negative net margin of 43,133.33%.

Cardio Diagnostics Stock Performance

CDIO remained flat at $1.68 during trading hours on Friday. 18,908 shares of the company traded hands, compared to its average volume of 23,643. The stock has a market cap of $4.96 million, a price-to-earnings ratio of -0.57 and a beta of 2.32. The stock’s 50-day moving average price is $1.84 and its 200 day moving average price is $2.06. Cardio Diagnostics has a 1 year low of $0.97 and a 1 year high of $7.91.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cardio Diagnostics in a research report on Tuesday, September 8th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc is a biotechnology company developing artificial intelligence-powered precision medicine products for the prevention and management of cardiovascular disease. Its approach combines genetic, epigenetic and clinical information to help identify individuals at elevated risk and support more personalized care.

The company’s product portfolio includes Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease and provide information that may guide prevention strategies.